Treatment of progressive stroke with tirofiban - Experience in 35 patients

Cerebrovascular Diseases

Volumn 28, Issue 5, 2009, Pages 435-438

  Philipps, Jörg ^a   Thomalla, Götz ^b   Glahn, Jörg ^a   Schwarze, Michael ^a   Röther, Joachim ^a  

^a KLINIKUM MINDEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antiplatelet drugs; Glycoprotein IIb IIIa inhibitor; Lacunar infarcts; Progressive stroke; Treatment

Indexed keywords

TIROFIBAN;

ADULT; AGED; ARTICLE; BLOOD VESSEL OCCLUSION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MALE; MICROCIRCULATION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; VASCULAR PATENCY;

AGED; ARTERIAL OCCLUSIVE DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICROCIRCULATION; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME; TYROSINE;

EID: 69749103912     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235987     Document Type: Article

References (13)

1. Caplan LR: Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology 1989; 39: 1246-1250.
2. Steinke W, Ley SC: Lacunar stroke is the major cause of progressive motor deficits. Stroke 2002; 33: 1510-1516.
3. Kim SK, Song P, Hong JM, Pak CY, Chung CS, Lee KH, Kim GM: Prediction of progressive motor deficits in patients with deep subcortical infarction. Cerebrovasc Dis 2008; 25: 297-303.
4. Abumiya T, Fitridge R, Mazur C, Copeland BR, Koziol JA, Tschopp JF, Pierschbacher MD, Del Zoppo GJ: Integrin alfa(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 2000; 31: 1402-1410.
5. Eckert B, Koch C, Thomalla G, Kucinski T, Grzyska U, Roether J, Alfke K, Jansen O, Zeumer H: Aggressive therapy with intravenous abciximab and intra-arteria rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion. Stroke 2005; 36: 1160-1165.
6. Straub S, Junghans U, Jovanovic V, Wittsack HJ, Seitz RJ, Siebler M: Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke 2004; 35: 705-709.
7. Junghans U, Seitz RJ, Aulich A, Freund HJ, Siebler M: Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis 2001; 12: 308-312.
8. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISMPLUS) Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Qwave myocardial infarction. N Engl J Med 1998; 338: 1488-1497.
9. Adams HP, the TOAST Investigators: Classification of subtype of acute ischemic stroke. Stroke 1993; 24: 35-41.
10. Adams HP, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W, for the AbESTTII Investigators: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial. Stroke 2008; 39: 87-99.
11. Knottnerus IL, ten Cate H, Lodder J, Kessels F, van Oostenbrugge RJ: Endothelial dysfunction in lacunar stroke: a systematic review. Cerebrovasc Dis 2009; 27: 519-526.
12. Hwang YH, Seo JG, Lee HW, Park SP, Suh CK: Early neurological deterioration following intravenous recombinant tissue plasminogen activator therapy in patients with acute lacunar stroke. Cerebrovasc Dis 2008; 26: 355-359.
13. Straub A, Azevedo R, Beierlein W, Wendel HP, Dietz K, Ziemer G: Tirofiban (Aggrastat) protects platelets and decreases plateletgranulocyte binding in an extracorporeal circulation model. Thorac Cardiovasc Surg 2006; 54: 162-167.